enGene Therapeutics Inc. Common Stock (ENGN) Stock
Key stats
- Market cap
- $120.63M
- Price / Earnings ratio
- -0.9x
- EPS (TTM)
- -$2.07
- Volume
- Loading
- 52-week high
- $12.25
- 52-week low
- $1.40
Source: third-party data provider, as of November 13, 2026
Compare with ENGN
Recent news

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
ENGN

enGene to Host KOL Webinar on October 15, 2026
enGene to Host KOL Webinar on October 15, 2026
ENGN

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
ENGN

enGene to Participate in Upcoming Investor Conferences
enGene to Participate in Upcoming Investor Conferences
ENGN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.62
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.03
- SMA 50
- $1.77
- Price above SMA 50
- EMA 50
- $1.76
- Price above EMA 50
- SMA 200
- $4.02
- Price below SMA 200
- EMA 200
- $4.17
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
ENGN

enGene to Host KOL Webinar on October 15, 2026
enGene to Host KOL Webinar on October 15, 2026
ENGN

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
ENGN

enGene to Participate in Upcoming Investor Conferences
enGene to Participate in Upcoming Investor Conferences
ENGN

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
ENGN

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
ENGN

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
ENGN

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
ENGN

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
ENGN

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
ENGN
News tone: automated (AI) classification of the article's content, not a price prediction.
About enGene Therapeutics Inc. Common Stock
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ronald H. W. Cooper | President, CEO & Director | 1963 |
| Dr. William J. Grossman M.D., Ph.D. | Interim Chief Medical Officer & Director | 1970 |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer | 1972 |
| Ms. Kathleen Richton | Senior VP of Finance, Principal Accounting & Financial Officer and Controller | 1978 |
| Ms. Joan Connolly | Chief Technology Officer | 1970 |
| Ms. Tara Place M.B.A. | Senior VP of Human Resources | — |
| Mr. Matthew Boyd | Chief Regulatory Officer | 1974 |
| Ms. Jill Buck | Chief Development Officer | 1974 |
| Ms. Amy Pott | Chief Global Commercialization Officer | 1976 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.62
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.03
- SMA 50
- $1.77
- Price above SMA 50
- EMA 50
- $1.76
- Price above EMA 50
- SMA 200
- $4.02
- Price below SMA 200
- EMA 200
- $4.17
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $4.00
- High
- $4.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.4 | -31.9 | +7.5 | -74.5 | -2.8 | +1.7 | +4.0 | +7.5 | -22.7 | +24.1 |



